Belimumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Belimumab" in French language version.

refsWebsite

Global rank French rank

222^nd place

129^th place

731^st place

771^st place

1,226^th place

347^th place

234^th place

147^th place

2^nd place

3^rd place

1sciencedirect.com

149^th place

80^th place

low place

low place

2,393^rd place

506^th place

bmj.com

ard.bmj.com

Manzi S, Sanchez-Guerrero J, Merrill JT et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials, Ann Rheum Dis, 2012;71:1833-1838
van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response, Ann Rheum Dis, 2012;71:1343-1349

doi.org

dx.doi.org

(en)Vincent FB, Morand EF and Mackay F, « BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus », Immunology and cell biology, 2012 (DOI 10.1038/icb.2011.111, consulté le 10 janvier 2012)

jrheum.org

Chatham WW, Wallace DJ, Stohl W et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial, J Rheumatol, 2012;39:1632-1640

nature.com

(en)Vincent FB, Morand EF and Mackay F, « BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus », Immunology and cell biology, 2012 (DOI 10.1038/icb.2011.111, consulté le 10 janvier 2012)

sagepub.com

lup.sagepub.com

Dooley MA, Houssiau F, Aranow C et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE, Lupus, 2013;22:63-72
Wallace DJ, Navarra S, Petri MA et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus, Lupus, 2013;22:144-154

sciencedirect.com

Davidson A, Targeting BAFF in autoimmunity, Curr Opin Immunol, 2010;22:732-739

thelancet.com

(en) Navarra SV, Guzmán RM, Gallacher AE, for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 2011;377:721-731

wiley.com

onlinelibrary.wiley.com

Jacobi AM, Huang W, Wang T et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study, Arthritis Rheum, 2010;62:201-210
Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum, 2011;63:3918-3930